STOCK TITAN

Lantheus Holding Stock Price, News & Analysis

LNTH Nasdaq

Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.

Lantheus Holdings, Inc. (NASDAQ: LNTH) is a global leader in radiopharmaceuticals and diagnostic imaging solutions, pioneering innovations in cardiovascular, oncology, and neurology diagnostics. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s strategic developments, financial performance, and clinical advancements.

Access authoritative coverage of LNTH’s earnings reports, regulatory milestones, and product launches. Our curated collection includes press releases on new imaging agents, partnership announcements with leading medical institutions, and updates on clinical trial progress. Discover how Lantheus’ precision diagnostics and radiopharmaceutical oncology solutions continue to shape modern medical imaging.

Key updates cover FDA approvals, international expansion efforts, and technological collaborations enhancing nuclear medicine capabilities. Bookmark this page for streamlined access to essential information about LNTH’s role in advancing diagnostic accuracy and therapeutic monitoring across global healthcare systems.

Rhea-AI Summary

Lantheus has appointed Jamie Spaeth as Chief People Officer, effective July 8, 2024. Ms. Spaeth joins the executive team, bringing nearly 20 years of HR experience in the biotech and pharma industries. Most recently, she served as Chief People Officer at Corium, a biopharmaceutical company.

Her responsibilities will include fostering a collaborative culture and supporting talent development to enhance Lantheus' strategy as a leading radiopharmaceutical-focused company. Ms. Spaeth's background includes roles at Sage Therapeutics and Shire, and she holds degrees in Hospitality and Tourism Management and Human Resources.

The addition of Ms. Spaeth is expected to strengthen Lantheus' leadership and support its mission of delivering better patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
management
-
Rhea-AI Summary

Lantheus Holdings, a leader in radiopharmaceuticals, has acquired global rights to Life Molecular Imaging's RM2, targeting the gastrin-releasing peptide receptor (GRPR) for prostate and breast cancers. The acquisition is valued at $35 million upfront with additional regulatory milestone payments and royalties. This deal enhances Lantheus' prostate cancer portfolio and introduces a new pipeline for breast and other cancers. RM2, including the radiotherapeutic 177Lu-DOTA-RM2 and the radiodiagnostic 68Ga-DOTA-RM2, has demonstrated favorable safety and dose-dependent efficacy. Lantheus plans to initiate a Phase 1/2a study in 2025, aiming to expand access to radiotheranostics for patients not suitable for PSMA-targeted therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
-
Rhea-AI Summary

Lantheus has announced that its AI-enabled aPROMISE software is now available on Siemens Healthineers’ syngo.via platform. The integration will be demonstrated at the SNMMI annual meeting in Toronto from June 8-11, 2024. aPROMISE is FDA-cleared software designed to analyze PSMA PET/CT images, providing quantitative data on disease burden, which aids in patient selection and monitoring for PSMA-targeted therapies. The availability on Siemens' platform aims to enhance clinical workflows across PET sites in the U.S.

Clinical studies have shown that aPROMISE supports patient selection for PSMA radioligand therapy and automates response monitoring over time. The software will be accessible via Siemens' OpenApps Digital Marketplace, facilitating advanced visualization and analysis in nuclear medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.49%
Tags
AI
Rhea-AI Summary

Lantheus, a leading radiopharmaceutical company, will present at the William Blair 44th Annual Growth Stock Conference. Paul Blanchfield, President of Lantheus, will deliver the presentation at 2:40 p.m. CT on June 4, 2024. Interested parties can access a live webcast or a replay on the company's website for at least 30 days following the event. This announcement highlights Lantheus' commitment to engaging with investors and sharing its growth strategies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.56%
Tags
conferences
-
Rhea-AI Summary

Lantheus (NASDAQ: LNTH) has announced the appointment of two new executives to accelerate its innovation efforts. Dr. Jeffrey S. Humphrey will join as Chief Medical Officer (CMO) and Dr. Jean-Claude Provost will take on the role of Chief Science Officer (CSO), both starting on May 28, 2024. Dr. Humphrey brings over 30 years of experience in clinical oncology and drug development, having worked with global pharmaceutical companies like Bayer and Pfizer. As CMO, he will oversee research and development, clinical development, and regulatory affairs. Dr. Provost, with a similar tenure of over 30 years, will focus on enhancing Lantheus’ pipeline and capabilities. Both appointees are expected to contribute significantly to Lantheus’ mission of better patient outcomes through innovative diagnostics and therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
none
-
Rhea-AI Summary

Lantheus Holdings, Inc. reported a 23.0% increase in worldwide revenue to $370.0 million for the first quarter of 2024 compared to the same period in 2023. The company achieved a GAAP fully diluted net income per share of $1.87, a significant improvement from a net loss per share of $0.04 in the first quarter of 2023. Adjusted fully diluted net income per share reached $1.69, up from $1.47 in the previous year. Lantheus also enhanced its full-year 2024 net revenue and earnings guidance while providing guidance for the second quarter of 2024. The company's strong financial position and market-leading commercial portfolio set the stage for continued growth through investments in current business operations, business development, and M&A opportunities in diagnostics and therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.01%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.41%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.11%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.23%
Tags
management

FAQ

What is the current stock price of Lantheus Holding (LNTH)?

The current stock price of Lantheus Holding (LNTH) is $74.41 as of July 16, 2025.

What is the market cap of Lantheus Holding (LNTH)?

The market cap of Lantheus Holding (LNTH) is approximately 5.7B.
Lantheus Holding

Nasdaq:LNTH

LNTH Rankings

LNTH Stock Data

5.70B
67.61M
2.74%
111.94%
9.26%
Drug Manufacturers - Specialty & Generic
In Vitro & in Vivo Diagnostic Substances
Link
United States
NORTH BILLERICA